 |
 |
 |
 |
 |
We are exploring apoptosis induced in B cell lines by antineoplastic drugs.
We suspect that induction of FAS ligand may play a role with one or more
drugs. Antibodies to FAS-L exist and an Fc fragment that inhibits binding of
FAS-L to the FAS receptor is also now available. My question is this: is it
enough to establish the FAS link by demonstrating a reduction in apoptosis
with either of these agents (the anti-FASL antibody or the Fc fragment) or is
it necessary to use both?
I appreciate any and all comments.
Thomas L. Morgan, Ph.D.
Department of Radiation Oncology
Kaiser Permanente Medical Center
4950 Sunset Blvd.
Los Angeles, CA 90027
213-667-3560
213-667-4568
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web